Stefano Gianoli

About Stefano Gianoli

I translate complex biological breakthroughs into actionable investment intelligence. As a PhD Immunologist at Harvard Medical School/BCH, I have pivoted from bench science to the strategic evaluation of therapeutic assets. I help VC firms, Biotech startups, and Pharma leaders answer the industry’s most high-stakes question:\"Is the science behind this asset robust enough to justify the capital?\"By combining deep technical rigor with a Search & Evaluation (S&E) mindset, I de-risk early-stage pipelines and map their commercial trajectory within the Boston/NYC biotech hubs.Why Work With Me:1) Scientific Due Diligence & Target Discovery: I perform deep-dive technical auditing of MoA, IP, and experimental validation. My recent research has identified high-impact targets in Sepsis (Metabolic Immunomodulation) and Rheumatoid Arthritis (Drug Resistance), addressing significant unmet medical needs.2) Search & Evaluation (S&E): Proven track record in identifying and vetting pharmacological targets, including a novel target for Acute Lung Injury (ALI) within a $4.3B projected market.3) AI-Driven Market Intelligence: I leverage Prompt Engineering and LLMs to accelerate competitive intelligence and scientific auditing, delivering data-driven insights 2x faster than traditional R&D workflows.4) Operational Resilience & Leadership: From managing $30k+ budgets and cross-functional teams at the BCH Postdoctoral Association to co-founding and scaling a university sports organization from the ground up, I thrive in high-bandwidth, high-pressure environments.Core Strategic Pillars: Asset De-risking: Technical auditing of Oncology, Autoimmunity, and Cell/Gene Therapy \"moonshots\" to ensure investment viability. Pipeline Strategy: Portfolio prioritization, competitive landscape analysis, and Go-to-Market (GTM) planning. Operational Leadership: 8+ years as a Volunteer EMT, developing the rapid decision-making skills and crisis management required in top-tier Consulting and VC firms.Background:PhD in Immunology (Summa Cum Laude)| Postdoc @ Harvard Medical School | Strategy Consultant @ TRI-I Consulting Club.Beyond the Boardroom:I believe precision and teamwork are universal. When I’m not evaluating assets, you can find me navigating the Atlantic as a Sailing Instructor at CBI Boston or capturing the world through a camera lens. I bring the same focus on tactical execution from the water to the boardroom.Let’s discuss the future of Life Sciences strategy: s••••••••@gmail.com | Boston, MA

Experience

1. Scientific Lead (Postdoctoral Fellow) Due Diligence & Strategy

   Boston Children's Hospital

   Nov 2023 — Present · Boston, MA, US

   Leveraging advanced immunology and AI-driven insights to de-risk early-stage biotech assets. Specialized in Scientific Due Diligence, Market Sizing, and Strategic Advisory for high-impact therapeutic areas. Bridging the gap between Harvard-led research and the Boston venture capital and consulting ecosystem.Key Achievements- Search & Evaluation | Asset De-risking: Directed the technical validation of a novel pharmacological target for acute lung injury. Performed Competitive Landscape Analysis for a therapeutic market projected at $4.3B (2035), aligning scientific milestones with investment viability- Operational Strategy & Cost Modeling: Engineered a clinical workflow optimization model that reduced projected ICU stays by 30%. Modeled an estimated $15K in savings per patient, demonstrating the ROI of translational process improvements- Strategic Grant Development: Key contributor to the development of an NIH R21 exploratory grant; synthesized complex biological data into high-level strategic proposals focused on therapeutic feasibility and clinical scalability- Strategic Advisory & Stakeholder Engagement: Acted as a technical consultant for department leadership, delivering biweekly briefs to senior stakeholders. Brokered 2 new external collaborations by identifying strategic synergies between academic research and industry needs- Project Leadership (Management Consulting Frameworks): Led a cross-functional team of 3 researchers, applying efficiency frameworks that boosted lab productivity by 43%. Managed timelines, quality compliance, and resource allocation under high-pressure deadlines.Conclusion:I am translating complex immunological research into high-impact business assets by combining technical due diligence with strategic market analysis to drive pipeline growth and operational ROI.

Education

• Università degli Studi di Milano

  Bachelor's degree, Medical Biotechnology

  2013 — 2016

• Università degli Studi di Milano

  Doctor of Philosophy - PhD, Experimental Medicine

  2019 — 2022

• Università degli Studi di Milano

  Master of Science - MS, Medical Biotechnology and Molecular Medicine

  2016 — 2018

• Harvard Medical School

  Postgraduate Degree, Immunology